2016 American Transplant Congress
Early Conversion to Everolimus in De Novo Renal Transplant Recipients: Incidence of Viral Infections in the Randomized-Controlled ELEVATE Study.
BackgroundCytomegalovirus (CMV) and BK polyomavirus (BKPyV) infections are independent risk factors for acute rejection and graft loss. Early conversion from calcineurin inhibitors (CNIs) to everolimus…2016 American Transplant Congress
Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal® with Prograf® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.
1SparTacus Study Group, Cologne, Germany; 2Novartis Pharma GmbH, Nuernberg, Germany.
Background: There is very limited evidence on the pharmacokinetic (PK) and clinical outcomes, comparing a generic tacrolimus with the standard reference drug in transplant (Tx)…2016 American Transplant Congress
IL-2 Therapy Restores the Impaired Function of Regulatory T Cells Induced by Calcineurin Inhibitors in Liver Transplantation.
Liver Science Department, King's College London, London, United Kingdom.
CD4+CD25+FOXP3+ regulatory T cells (Tregs) have an essential role in immune regulation and constitute a key target for cellular immunotherapies in transplantation. IL-2 is critical…2016 American Transplant Congress
The Effect of Spironolactone on Calcineurininhibitor Induced Nephrotoxicity.
Purpose: Evidence points towards activation of the mineralocorticoid receptor (MR) to be involved in CNI nephrotoxicity. The SPIREN trial was designed to test the hypothesis…2016 American Transplant Congress
Impact of Low Dose Tacrolimus with Everolimus Regimen on Renal Pathology and T-Regulatory Cells in Kidney Transplant.
Calcineurin inhibitors (CNI) serve as the cornerstone of immunosuppression (IS) after kidney transplant. However chronic CNI nephrotoxicity has been implicated in allograft dysfunction. We hypothesize…2016 American Transplant Congress
Impact on Wound Healing Events After Early Conversion to Everolimus in De Novo Renal Transplant Recipients: 24-Month Results from the Randomized ELEVATE Study.
BackgroundWound healing events (WHE) are probably the most common type of post-transplant (Tx) surgical complication. Due to its antiproliferative properties, mammalian target of rapamycin inhibitors…2016 American Transplant Congress
The Use of Sofosbuvir (SOF)-Containing Direct Antiviral Agents (DAA)-Based Regimens Requires Increase in Tacrolimus (Tac) Doses in Kidney Transplant (KT) Recipients with Hepatitis C Virus (HCV) Infection.
Background: The use of SOF-containing regimens based on NS5A inhibitors has not been shown interactions with Tac in liver transplant.Specific data on KT recipients are…2016 American Transplant Congress
Prospective Randomized Study of a Steroid Free, Low Dose Tacrolimus with Everolimus Regimen in Kidney Transplant.
Northwestern University, Chicago, IL; University of Virginia, Chicago, IL.
Calcineurin inhibitors (CNI) serve as the cornerstone of immunosuppression (IS) after kidney transplant. However chronic CNI nephrotoxicity has been implicated in allograft dysfunction. We hypothesize…2016 American Transplant Congress
Everolimus and Low Dose Cyclosporine Immunosuppressive Regimen and Development of Anti HLA Donor Specific Antibodies.
Few data are available on the rate of de novo anti-HLA donor specific antibodies (DSA) with the use of everolimus in kidney transplant recipients.MaterialsWe selected…2016 American Transplant Congress
Calcineurin Inhibitor (CNI) Delay with ATG Induction: Teaching an Old Dog, New Tricks.
CNI delay early after heart transplantation is a recommended therapeutic option according to ISHLT guidelines. However, there exist only few published data on feasibility of…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- 16
- Next Page »